OXBDF - Oxford Biomedica plc (OXBDF) Q4 2023 Earnings Call Transcript
2024-04-29 13:05:24 ET
Oxford Biomedica plc (OXBDF)
Q4 2023 Earnings Conference Call
April 29, 2024 08:00 ET
Company Participants
Frank Mathias - Chief Executive Officer
Sébastien Ribault - Chief Commercial Officer
Stuart Paynter - Chief Financial Officer
Thierry Cournez - Chief Operating Officer
Conference Call Participants
Charles Weston - RBC
John Priestner - JPMorgan
Max Herman - Stifel
Julie Simmonds - Panmure Gordon
Paul Cuddon - Numis Securities
Myles Dixon - Peel Hunt
Presentation
Frank Mathias
Good afternoon, everyone. And obviously, good morning to those on the other side of the ocean. Thank you so much for joining today's Analyst Briefing of our 2023 Preliminary Results.
I am Frank Mathias, the COO of Oxford Biomedica. And it's a pleasure to see so many familiar faces here in this room; so thank you for coming. To be here to speak to those on the webcast and those joining via the conference call lines today; with me I have our Chief Financial Officer, Stuart Paynter; our Chief Commercial Officer, Dr. Sébastien Ribault. And I'm also proud for the first time to have joining me, Thierry Cournez, our relatively new appointed Chief Operating Officer, who is also in charge of the UK operations. As I believe that you have all met Stuart and Sébastien before, I will Thierry introduce himself when he starts his section of the presentation shortly.
So looking at 2023, it's obvious that 2023 was a year of transformation for Oxford Biomedica, as we began building a global pure place, cell and gene therapy CDMO. Throughout the year, we have met significant milestones and celebrated many successes which have provided me and the Board with confidence in our new strategy and it’s ability to deliver long-term sustainable growth. I will begin this presentation by highlighting these achievements and the progress we have made to transform the company before handing over to Thierry to discuss integration and transformation of our global operations in greater detail. Sébastien will then provide an update on the strong momentum we are seeing on the commercial side. And Stuart, finally, will give an overview of our financial performance for the year and also a mid-term outlook.
So this obviously, yeah -- right. Okay. So, mission; as you know, at the core of our -- at Oxford Biomedica [ph], we have our mission to enable our clients to deliver life changing therapies to patients. This mission underpins incredibly important work we do and the strategies that we're implementing is geared towards helping us achieving this by providing best in class CDMO practices and accelerating the time it takes to our clients to bring their treatment to the markets. I will return to a slide we showed in September last year; for our interims presentation when we announced our three pillar plan....
Oxford Biomedica plc (OXBDF) Q4 2023 Earnings Call Transcript